论文部分内容阅读
为了研究Ｐ５３基因突变与子宫内膜癌的关系，本研究应用免疫组化Ｓ－Ｐ法检测了６４例子宫内膜癌，１６例正常子宫内膜，３２例子宫内膜增殖症及５例子宫内膜息肉组织中Ｐ５３蛋白表达情况。结果：突变型Ｐ５３蛋白在子宫内膜癌组织中的阳性率为３７．５％，而在正常子宫内膜、子宫内膜单纯性及复合性增生、内膜息肉中均阴性，不典型增生１例（１／３）阳性。突变型Ｐ５３阳性表达与临床分期、组织学级别相关，与病理类型、肌层浸润无关。Ｐ５３阳性表达患者的３年、５年生存率明显低于阴性患者（Ｐ＜０．０１）。认为突变型Ｐ５３与子宫内膜癌恶性生物学行为相关，可以作为判断子宫内膜癌的恶性程度及评估预后的指标
In order to study the relationship between P53 gene mutation and endometrial cancer, 64 cases of endometrial cancer, 16 cases of normal endometrium, 32 cases of endometrial hyperplasia and 5 cases of uterus were detected by immunohistochemical S-P method. Expression of P53 protein in endometrial polyps. RESULTS: The positive rate of mutant P53 protein in endometrial carcinoma was 37.5%, but it was negative in normal endometrium, simple and composite endometrial hyperplasia, endometrial polyps, dysplasia 1 Cases (1/3) are positive. The positive expression of mutant P53 was associated with clinical stage and histological grade, but not with histological type and muscular infiltration. The 3-year and 5-year survival rates of patients with positive P53 expression were significantly lower than those of negative patients (P<0.01). It is thought that mutant P53 is associated with malignant biological behavior of endometrial carcinoma and can be used as an indicator to judge the malignancy of endometrial carcinoma and evaluate its prognosis.